Breast Cancer Clinical Trial
Official title:
Efficacy and Feasibility of a Psychosocial Intervention Within the CCOP Context: Evaluation of the Facing Forward Guide to Facilitate Life After Active Cancer Treatment
RATIONALE: Printed educational materials, such as the Facing Forward Series: Life After
Cancer Treatment manual, may help make the transition from cancer patient to cancer survivor
easier in patients who are finishing treatment for cancer. It is not yet known if the Facing
Forward Series: Life After Cancer Treatment manual and The Cancer Information Service,
Questions and Answers fact sheet is more effective than the The Cancer Information Service,
Questions and Answers fact sheet alone in helping to make life after cancer treatment easier
and to improve quality of life in patients with breast cancer, colorectal cancer, prostate
cancer, or chest cancer.
PURPOSE: This randomized clinical trial is studying how well printed education materials work
in assisting patients who are finishing treatment for stage I, stage II, or stage IIIA breast
cancer, colorectal cancer, prostate cancer, or chest cancer to make the transition from
cancer patient to cancer survivor easier.
OBJECTIVES:
Primary
- Determine the efficacy of a psychoeducational intervention comprising a specific print
intervention manual (Facing Forward Series: Life After Cancer Treatment [Facing Forward
manual]) and a general print intervention fact sheet (The Cancer Information Service,
Questions and Answers) vs the general print intervention fact sheet only on the uptake
of recommended actions (e.g., developing a wellness plan after treatment, dealing with
pain and fatigue, finding support groups to deal with feelings after treatment, and
dealing with family issues after treatment) in patients completing active treatment for
stage I-IIIA breast, prostate, colorectal, or thoracic cancer.
- Explore patient process evaluations of the Facing Forward manual in terms of its
usability, comprehension, and satisfaction.
Secondary
- Examine psychological outcomes (i.e., depressive symptoms, fear of recurrence,
health-related quality of life, and self-efficacy) as a function of exposure to the
Facing Forward manual.
OUTLINE: This is a multicenter, randomized, controlled, open-label, cohort study. Patients
are stratified according to participating center, prior chemotherapy (yes vs no), and type of
cancer (breast vs colorectal vs prostate vs thoracic). Patients are randomized to 1 of 2
arms.
- Arm I (intervention): Patients receive a specific print intervention manual entitled
Facing Forward Series: Life After Cancer Treatment and a general print intervention fact
sheet entitled The Cancer Information Service, Questions and Answers.
- Arm II (control): Patients receive the general print intervention fact sheet entitled
The Cancer Information Service, Questions and Answers.
In both arms, patients are evaluated at baseline (within 18 days of the patient's final
cancer treatment visit), 8 weeks (via mailed home materials), and then at 6 months (via
mailed home materials). Baseline evaluations include background information (i.e.,
demographics and medical status), baseline use of educational materials, survivorship
activities, and psychological factors (i.e., depressive symptoms, quality of life, fear of
recurrence, and self-efficacy). Psychological factors are also reassessed at 8 weeks and 6
months, as well as use of educational materials and survivorship activities.
For patients in both arms, uptake of recommended actions are reassessed. Patients in arm I
complete ratings of the Facing Forward Series: Life After Cancer Treatment manual usability,
comprehension, and satisfaction at 8 weeks and 6 months.
PROJECTED ACCRUAL: A total of 332 patients will be accrued for this study.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |